文献速递骨软组织肉瘤与黑色素瘤

伊匹木单抗治疗癌症患者的治疗相关死亡风险:系统综述与Meta分析

Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2017-07-15

该系统综述与Meta分析纳入12项随机对照试验、共5775例实体瘤患者,评估伊匹木单抗相关致死性不良事件(FAE)风险。伊匹木单抗组FAE合并发生率为1.13%(95%CI 0.56-1.86),对照组为0.22%;合并Peto OR为2.3(95%CI 1.4-3.6;P<0.001),提示伊匹木单抗与治疗相关死亡风险升高相关。

要点

  • 伊匹木单抗组FAE合并发生率1.13%(95%CI 0.56-1.86),对照组为0.22%。
  • 伊匹木单抗与FAE风险升高相关,合并Peto OR为2.3(95%CI 1.4-3.6;P<0.001)。
  • 伊匹木单抗与致死性胃肠道毒性风险升高相关,OR为4.5(95%CI 1.5-13.6)。

核心结论

  • 与对照组相比,使用伊匹木单抗与治疗相关死亡风险升高相关。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE、Cochrane CENTRAL、ClinicalTrial.gov及会议论文集,检索时间自建库至2016年12月。
  • 纳入将患者随机分配至伊匹木单抗治疗(联合或不联合同期治疗)或对照、且具有FAE发生率数据的前瞻性随机对照试验。
  • 共纳入12项随机对照试验、5775例实体瘤患者,其中10项来自期刊报告、2项来自ClinicalTrials.gov;由两名评价者独立提取数据。

主要发现

  • 伊匹木单抗组FAE合并发生率为1.13%(95%CI 0.56-1.86),对照组为0.22%。
  • 伊匹木单抗与FAE风险升高相关,合并Peto OR为2.3(95%CI 1.4-3.6;P<0.001)。
  • 按肿瘤类型(黑色素瘤对比其他肿瘤)、治疗方式(联合治疗或单药治疗)、对照类型(活性对照对比安慰剂或仅最佳支持治疗)及伊匹木单抗剂量(高剂量对比低剂量[10对比3 mg/kg,每3周一次])进行亚组分析,均未发现统计学显著的亚组间差异。
  • 伊匹木单抗与致死性胃肠道毒性风险升高相关,OR为4.5(95%CI 1.5-13.6)。

关键数值与推荐

  • FAE发生率采用随机效应模型合并,伊匹木单抗相关FAE风险采用Peto OR估计。
  • 伊匹木单抗组FAE合并发生率为1.13%(95%CI 0.56-1.86),对照组为0.22%。
  • 伊匹木单抗与FAE风险升高相关,合并Peto OR为2.3(95%CI 1.4-3.6;P<0.001)。
  • 伊匹木单抗与致死性胃肠道毒性风险升高相关,OR为4.5(95%CI 1.5-13.6)。
  • 亚组分析(肿瘤类型、治疗方式、对照类型、伊匹木单抗剂量[10对比3 mg/kg,每3周一次])未发现统计学显著的亚组间差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fatal adverse events (FAEs) have been reported in cancer patients receiving ipilimumab-a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, but the risk of treatment-related mortality is unknown. We performed a systematic review and meta-analysis of randomised controlled trials (RCTs) of ipilimumab to determine the overall risk of FAEs associated with ipilimumab. METHODS: We systematically searched MEDLINE, EMBASE, Cochrane CENTRAL, ClinicalTrial.gov and conference proceedings from inception to December 2016, for prospective trials that randomly assigned patients to ipilimumab treatment (with or without concurrent therapy) or controls with available data regarding incidence of FAEs. Two reviewers extracted data independently. Incidence of FAEs was pooled using a random effects model, and the risk of FAEs associated with ipilimumab was estimated using Peto odds ratios (ORs). RESULTS: A total of 5775 patients with solid tumours included in 12 RCTs (10 from journal reports and 2 from ClinicalTrials.gov) were included in the meta-analysis. The pooled incidence of FAEs for patients treated with ipilimumab was 1.13% (95% confidence interval [CI], 0.56-1.86), compared with 0.22% in the control arms. Ipilimumab was associated with statistically significantly increased risk of FAEs, with a pooled Peto OR of 2.3 (95% CI, 1.4-3.6; P < 0.001). Analyses according to cancer type (melanoma versus other cancers); treatment mode (combination therapy or monotherapy); control type (active control versus placebo/best supportive care only); ipilimumab dose (high versus low dose [10 versus 3 mg/kg every 3 weeks]) found no statistically significantly differential effect by subgroups. Among the specific causes of FAEs, ipilimumab was associated with an increased risk of fatal gastrointestinal toxicity, with an OR of 4.5 (95% CI, 1.5-13.6). CONCLUSION: The use of ipilimumab, compared with controls, was associated with increased risk of treatment-related mortality.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zhang S, Liang F, Li W, et al. Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis. Eur J Cancer. 2017. PMID: 28719841. doi:10.1016/j.ejca.2017.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。